GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lifecore Biomedical Inc (NAS:LFCR) » Definitions » Asset Turnover

Lifecore Biomedical (Lifecore Biomedical) Asset Turnover : 0.10 (As of May. 2023)


View and export this data going back to 1996. Start your Free Trial

What is Lifecore Biomedical Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Lifecore Biomedical's Revenue for the three months ended in May. 2023 was $25.5 Mil. Lifecore Biomedical's Total Assets for the quarter that ended in May. 2023 was $244.8 Mil. Therefore, Lifecore Biomedical's Asset Turnover for the quarter that ended in May. 2023 was 0.10.

Asset Turnover is linked to ROE % through Du Pont Formula. Lifecore Biomedical's annualized ROE % for the quarter that ended in May. 2023 was -949.29%. It is also linked to ROA % through Du Pont Formula. Lifecore Biomedical's annualized ROA % for the quarter that ended in May. 2023 was -58.11%.


Lifecore Biomedical Asset Turnover Historical Data

The historical data trend for Lifecore Biomedical's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lifecore Biomedical Asset Turnover Chart

Lifecore Biomedical Annual Data
Trend May14 May15 May16 May17 May18 May19 May20 May21 May22 May23
Asset Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.21 0.30 0.19 0.29 0.39

Lifecore Biomedical Quarterly Data
Aug18 Nov18 Feb19 May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.07 0.16 0.14 0.11 0.10

Competitive Comparison of Lifecore Biomedical's Asset Turnover

For the Drug Manufacturers - Specialty & Generic subindustry, Lifecore Biomedical's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lifecore Biomedical's Asset Turnover Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Lifecore Biomedical's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Lifecore Biomedical's Asset Turnover falls into.



Lifecore Biomedical Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Lifecore Biomedical's Asset Turnover for the fiscal year that ended in May. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: May. 2023 )/( (Total Assets (A: May. 2022 )+Total Assets (A: May. 2023 ))/ count )
=103.269/( (274.703+253.545)/ 2 )
=103.269/264.124
=0.39

Lifecore Biomedical's Asset Turnover for the quarter that ended in May. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: May. 2023 )/( (Total Assets (Q: Feb. 2023 )+Total Assets (Q: May. 2023 ))/ count )
=25.521/( (236.153+253.545)/ 2 )
=25.521/244.849
=0.10

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Lifecore Biomedical  (NAS:LFCR) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Lifecore Biomedical's annulized ROE % for the quarter that ended in May. 2023 is

ROE %**(Q: May. 2023 )
=Net Income/Total Stockholders Equity
=-142.284/14.9885
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-142.284 / 102.084)*(102.084 / 244.849)*(244.849/ 14.9885)
=Net Margin %*Asset Turnover*Equity Multiplier
=-139.38 %*0.4169*16.3358
=ROA %*Equity Multiplier
=-58.11 %*16.3358
=-949.29 %

Note: The Net Income data used here is four times the quarterly (May. 2023) net income data. The Revenue data used here is four times the quarterly (May. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Lifecore Biomedical's annulized ROA % for the quarter that ended in May. 2023 is

ROA %(Q: May. 2023 )
=Net Income/Total Assets
=-142.284/244.849
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-142.284 / 102.084)*(102.084 / 244.849)
=Net Margin %*Asset Turnover
=-139.38 %*0.4169
=-58.11 %

Note: The Net Income data used here is four times the quarterly (May. 2023) net income data. The Revenue data used here is four times the quarterly (May. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Lifecore Biomedical Asset Turnover Related Terms

Thank you for viewing the detailed overview of Lifecore Biomedical's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Lifecore Biomedical (Lifecore Biomedical) Business Description

Traded in Other Exchanges
N/A
Address
3515 Lyman Boulevard, Chaska, MN, USA, 55318
Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that offers highly differentiated capabilities in the development, fill and finish of complex sterile injectable pharmaceutical products in syringes and vials. It manufactures injectable-grade Hyaluronic Acid.
Executives
Raymond T. White director 12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Legion Partners, Llc director 12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Legion Partners Holdings, Llc director 12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Legion Partners, L.p. Ii director 12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Legion Partners, L.p. I director 12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Legion Partners Asset Management, Llc director 12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Christopher S Kiper director 12121 WILSHIRE BLVD, SUITE 1240, LOS ANGELES CA 90025
Nathaniel Calloway director C/O ANEBULO PHARMACEUTICALS, INC., 1415 RANCH ROAD 620 SOUTH, SUITE 201, LAKEWAY TX 78734
Wynnefield Partners Small Cap Value Lp I 10 percent owner 450 SEVENTH AVENUE, SUITE 509, NEW YORK NY 10123
Raymond H Diradoorian director C/O LANDEC CORPORATION, 2811 AIRPARK DRIVE, SANTA MARIA CA 93455
Joshua Schechter director C/O THE PANTRY, INC., 305 GREGSON DRIVE, CARY NC 27511
Patrick D Walsh director 14282 FRANKLIN AVE., TUSTIN CA 92780
John D Morberg officer: Chief Financial Officer C/O LANDEC CORPORATION, 2811 AIRPARK DRIVE, SANTA MARIA CA 93455
Albert D. Bolles director CONAGRA FOODS, INC., ONE CONAGRA DRIVE, MS 1-330, OMAHA NE 68102
James G Hall officer: Executive Vice President 3515 LYMAN BLVD., CHASKA MN 55318